RecruitingNot ApplicableNCT06207591

Investigation on the Cortical Communication System

Investigation on the Cortical Communication (CortiCom) System


Sponsor

UMC Utrecht

Enrollment

2 participants

Start Date

Dec 15, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems. The main questions it aims to answer are efficient and stable control of Brain-Computer interface (BCI) functions for communication with attempted hand movements and operation of a keyword-based speech BCI. Participants will be implanted with four electrode grids, with in total 128 electrodes, on the surface of the brain and a connector on the skull. Participation includes visits of researchers for recording and training at home, 2-3 times per week for one year. Extension of participation after one year is possible. If successful, the participant will be able to use the BCI at home independently, without the presence of a researcher.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called ECoG (electrocorticography) sensing for people with brainstem stroke, neuromuscular diseases, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEECoG (electrocorticography) sensing

Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI


Locations(1)

University Medical Center

Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06207591


Related Trials